Annovis Bio raises ~$6M in registered direct offering of 4M shares/pre-funded warrants at $1.50/share

Annovis Bio, Inc.

Offering comprises 3.15M shares and 850K pre-funded warrants at $1.50 per share (warrant price $1.4999); gross proceeds ~$6M.
Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease, working capital, and general corporate purposes.
H.C. Wainwright acts as exclusive placement agent; 7% cash fee plus 200K warrants exercisable at $2.20 per share for 5 years.
Officers and directors subject to 45-day lock-up from closing date, which is expected on or about October 13-14, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.